| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 729.1 | 682.8 | 559.1 |
| Other income | 15.1 | 9.2 | 6.2 |
| Total income | 744.2 | 692.0 | 565.3 |
| Profit before exceptional items & tax | 103.5 | 51.0 | 78.1 |
| Exceptional items | -15.0 | -0.2 | -5.3 |
| Profit before tax | 88.5 | 50.8 | 72.8 |
| Net profit | 62.3 | 37.9 | 54.2 |
| Operating margin | 11.9% | 7.3% | 12.9% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +14.90% |
|---|---|
| Net profit, quarter on quarter | +64.40% |
| Revenue, year on year | +30.40% |
| Operating profit, year on year | +22.90% |
| Operating profit, quarter on quarter | +111.50% |
BSE results filing, NSE: ASTRAZEN. Figures extracted from the filing.
AstraZeneca Pharma India Ltd: key numbers
- Share price
- ₹6,294.00
- Market cap
- ₹15,735 Cr
- Revenue (annual)
- ₹2,276 Cr
- Net profit (annual)
- ₹187.5 Cr
- P/E (TTM)
- 92.8×Sector 37.9×
- Promoter holding
- 75.00%+0.00% QoQ
- FII holding
- 2.64%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from AstraZeneca Pharma India Ltd
All →AstraZeneca Pharma India Results Update
AstraZeneca Pharma India reported 30% growth in Q2 results, with three new regulatory approvals. It also announced MoUs with two state governments.
AstraZeneca Pharma India Legal & Regulatory
Delhi High Court directed NPPA to refrain from coercive steps on Rs.151.20 Crore alleged Symbicort Turbuhaler overcharging. Next hearing is January 11, 2027.
- Value
- ₹151.2 Cr
AstraZeneca Pharma India Other Announcement
AstraZeneca Pharma India filed its quarterly shareholding pattern for the period ended 30 September 2026. Promoter and promoter group hold 75% of total equity.
AstraZeneca Pharma India Board Meeting Date
AstraZeneca Pharma India scheduled its board meeting for 5 Nov 2026 to approve Q2/H1 FY27 results. The trading window remains closed until 7 Nov 2026.
AstraZeneca Pharma India Capacity Expansion
AstraZeneca Pharma India inaugurated a new corporate office in Mumbai, covering 25,600 sq ft. This expansion strengthens the company's commercial operations and footprint in India.
- office space
- 25600.0 sq ft
AstraZeneca Pharma India Annual General Meeting
AstraZeneca Pharma India Ltd declared the voting results of its postal ballot, confirming the appointment and designation change of certain non-executive directors.